UNSPSC 51162745: Tiopronin

This classification denotes an agent affecting blood and body fluid with the molecular formula C5H9NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) C5W04GO61S, chemically known as glycine, n-(2-mercaptopropionyl)- but more generally known as tiopronin, which bears US NIH Compound Identifier 5483. European Medicines Agency schedules Tiopronin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11089MIG. The term TIOPRONIN is an International Non-Proprietary Name.

UNSPSC 51162745 Tiopronin is a Commodity code under which state and local governments procure pharmaceutical products, specifically branded and generic medications for distribution through public health systems, emergency response programs, and cooperative purchasing alliances. Recent solicitations show state and local buyers acquiring naloxone (an opioid overdose reversal agent) and related pharmaceutical products through competitive bidding processes and multi-state cooperative agreements. The issuing bodies span county health departments and state-administered cooperative purchasing organizations, with solicitations emphasizing compliance with cGMP, FDA requirements, DEA regulations, and drug supply chain security standards. Vendors must maintain authorized wholesaler relationships, demonstrate pricing flexibility across multiple pricing models, and hold substantial insurance coverage including commercial general liability of $5,000,000 per occurrence.

Activity under this code appears concentrated in the Southeast and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 to establish multi-vendor contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. The MMCAP solicitation required products available by May 15, 2026, and weighted price competitiveness at 75 percent of evaluation criteria. Neither solicitation identified explicit set-aside designations for disadvantaged enterprises.